- Home
- YHGJ vs CMMB Comparison
YHGJ vs CMMB Comparison
Compare YHGJ & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YHGJ | CMMB |
|---|---|---|
| Founded | 1975 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2M | 10.2M |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | YHGJ | CMMB |
|---|---|---|
| Price | $3.54 | $1.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $26.50 |
| AVG Volume (30 Days) | 18.1K | ★ 68.5K |
| Earning Date | 11-13-2025 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,377,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.41 | N/A |
| 52 Week Low | $3.37 | $1.54 |
| 52 Week High | $12.70 | $8.76 |
Technical Indicators
Market Signals| Indicator | YHGJ | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 42.83 | 39.20 |
| Support Level | $3.43 | $1.66 |
| Resistance Level | $3.92 | $1.83 |
| Average True Range (ATR) | 0.34 | 0.14 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 11.89 | 34.35 |
Price Performance
Historical ComparisonAbout YHGJ Yunhong Green CTI Ltd.
Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.